文章：

对来那度胺一线治疗进展的多发性骨髓瘤患者的治疗

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

原文发布日期：2019-03-20

DOI: 10.1038/s41408-019-0200-1

类型: Article

开放获取: 是

英文摘要：

Over the last years, there has been great progress in the treatment of multiple myeloma with many new agents and combinations having been approved and being now routinely incorporated into treatment strategies. As a result, patients are experiencing benefits in terms of survival and better tolerance. However, the multitude of treatment options also presents a challenge to select the best options tailored to the specific patient situation. Lenalidomide is increasingly being used as part of frontline therapy in newly diagnosed multiple myeloma. This agent is typically administered until disease progression. It is currently unclear, how to best manage patients, who relapse while receiving lenalidomide as part of their frontline treatment. We conducted a review to summarize the available evidence in this setting. Our summary shows that there are very few data from current trials testing new combinations based on carfilzomib, pomalidomide, or daratumumab that address this specific patient population. Our review is aimed to summarize the available evidence to assist treatment decision making and to raise awareness of this lack of data to encourage further analyses and the incorporation of sequencing questions in future trial designs.
 

摘要翻译： 

近年来，多发性骨髓瘤的治疗取得了重大进展，许多新药和联合疗法已获批并常规纳入治疗策略。因此，患者在生存期和耐受性方面获得了益处。然而，众多的治疗选择也对根据患者具体情况选择最佳方案提出了挑战。来那度胺越来越多地作为新诊断多发性骨髓瘤的一线治疗组成部分。该药物通常持续使用至疾病进展。目前尚不清楚如何最有效地管理在接受来那度胺作为一线治疗期间复发的患者。我们进行了一项综述，以总结该领域的现有证据。我们的总结表明，目前基于卡非佐米、泊马度胺或达雷木单抗的新联合方案试验中，针对这一特定患者群体的数据非常有限。本综述旨在总结现有证据以协助治疗决策，并提高对这一数据缺失的认识，以鼓励进一步分析并将治疗顺序问题纳入未来的试验设计。

原文链接：

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide